How will the semaglutide patent expiry impact the market?

How long until semaglutide patents expire?

Novo Nordisk’s core patents on semaglutide expire between 2026 and 2032 in the United States. The first key patent covering the molecule itself is set to lapse in 2026, while formulation and delivery-device patents extend later. Generic or biosimilar manufacturers are already filing patent challenges to accelerate entry.

Why are companies challenging these patents?

Patent challengers argue that certain formulation claims are obvious or lack sufficient novelty. Early court rulings have upheld some Novo patents, but litigation continues. A successful challenge could open the market to lower-cost versions as early as 2026, especially if regulatory pathways for complex peptide generics or biosimilars are clarified.

How will prices change once generics or biosimilars arrive?

Current list prices for Ozempic and Wegovy exceed $1,000 per month. Historical examples with other peptides show price drops of 30–80 % once competition begins. Analysts project similar reductions for semaglutide, though the extent will depend on how many competitors gain approval and whether payers demand deep discounts.

What barriers could delay cheaper versions?

Semaglutide is a peptide produced via recombinant technology, so regulators may require biosimilar rather than generic approval pathways. Manufacturing complexity, cold-chain logistics, and the need for new drug-delivery devices could slow market entry. Additionally, Novo is developing next-generation molecules and new patents that may extend exclusivity.

How are competitors positioning themselves?

Eli Lilly’s tirzepatide (Mounjaro, Zepbound) holds separate patents that run into the 2030s. Other firms are developing oral or once-weekly peptide analogs. Several Chinese and Indian manufacturers have announced semaglutide biosimilar programs aimed at both domestic and export markets once U.S. and EU patents lapse.

What happens to patient access and insurance coverage?

Once multiple lower-cost versions exist, insurers are expected to shift preferred status to the cheapest product. Medicare Part D plans may add coverage for weight-management indications if prices fall below current thresholds. Out-of-pocket costs for uninsured patients could drop sharply, though supply constraints may persist for several years after first generic entry.

When does exclusivity expire for related products?

Rybelsus oral tablets rely on the same active-ingredient patents, so the 2026 date applies. Device-specific patents for the Ozempic and Wegovy pens extend further, potentially delaying fully substitutable competition until 2029–2032. Novo continues to file new patents on improved formulations, creating a rolling exclusivity landscape.

Can biosimilars launch before the last patent expires?

Under the Biologics Price Competition and Innovation Act, biosimilars may file for approval 12 years after the reference product’s first licensure. If any semaglutide product receives new biologic designation, the 12-year clock restarts. Most analysts expect the first U.S. launch in 2026–2027 if patent challenges succeed, with broader availability after 2028.

[1] https://www.drugpatentwatch.com/patent/semaglutide
[2] https://www.drugpatentwatch.com/blog/semaglutide-patent-expiry-2026